Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0162316 (
iron deficiency anemia
)
3,806
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Iron deficiency anemia
(
IDA
) is a common nutritional disease suffered by 1 billion people. To develop a new drug which avoids the side effects of traditional oral iron supplementation for
IDA
treatment, we have designed Fe
3
O
4
@ Astragalus polysaccharide core-shell nanoparticles (Fe
3
O
4
@APS NPs) and demonstrated them to be an efficient therapeutic drug for
IDA
treatment in vivo. The Fe
3
O
4
@APS NPs have been successfully synthesized with good water solubility and stability, especially in imitated digestion. Cytotoxicity assessment in cells and pathological tests in mice justify their good biocompatibility and low toxicity. The
IDA
treatment in rats shows that they have efficient therapeutic effect, which is contributed to both the iron element supplement from Fe
3
O
4
and the APS-stimulated hematopoietic cell generation. Moreover, the superparamagnetic Fe
3
O
4
@APS NPs are capable for use as a magnetic resonance imaging contrast agent. This study presents the possibility of nanocomposites involving purified natural products from Chinese herb medicine for biomedical applications.
ACS
Appl Mater Interfaces 2019 Mar 20
PMID:Fe
3
O
4
@ Astragalus Polysaccharide Core-Shell Nanoparticles for Iron Deficiency Anemia Therapy and Magnetic Resonance Imaging in Vivo. 3080 Nov 82
